TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing

Cancer Genomics - Proteomics

SI-YI CHEN²  XUE HUANG²  ZHENFEN SHI³  JINGBO ZHANG³  YANGYANG LI³  LIFENG LIU¹  JINGWEN LI¹  GUANGCHUN ZHANG³  LINDSEY JONES²  HE YAN³  BAISHUAI GUO³  HAICHAO DONG³  CHAO ZHANG¹  DANDAN ZHANG³  YAN WANG¹  HUILI ZHENG¹  QINGYU LU³  ZHENCONG LIU¹  CHUANNING TANG³  ZHIYUAN LIU³  HUA YE³  FENG LOU³  ZHISHOU DONG³  WEIHAI CAO¹  HONG SUN³ 

[1] he First Hospital of Qiqihar, Qiqihar, P.R. Chinahe First Hospital of Qiqihar, Qiqihar, P.R. Chinahe First Hospital of Qiqihar, Qiqihar, P.R. China;orris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.orris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.orris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.;an Valley Biotechnology Inc., Beijing, P.R. Chinaan Valley Biotechnology Inc., Beijing, P.R. Chinaan Valley Biotechnology Inc., Beijing, P.R. China

关键词: Esophageal cancer;    next-generation sequencing;    Ion PGM;    genetic mutations;    targeted therapy;    personalized medicine;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

Background/Aim: Esophageal cancer (EC) is a common malignancy with significant morbidity and mortality. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in EC that may serve as biomarkers might help predict patient outcome and guide treatment. Traditionally, personalized cancer DNA sequencing was impractical and expensive. Recent technological advancements have made targeted DNA sequencing more cost- and time-effective with reliable results. This technology may be useful for clinicians to direct patient treatment. Materials and Methods: The Ion PGM and AmpliSeq Cancer Panel was used to identify mutations at 737 hotspot loci of 45 cancer-related genes in 64 EC samples from Chinese patients. Results: Frequent mutations were found in TP53 and less frequent mutations in PIK3CA, FBXW7 and KRAS. Conclusion: These results demonstrate that targeted sequencing can reliably identify mutations in individual tumors that make this technology a possibility for clinical use.

【 授权许可】

Unknown